BD Marks Milestone with First Phasix™ Hernia Prevention Case in Greece and Over 85% Enrollment in U.S. PREVENT Trial

Rhea-AI Summary

BD (NYSE: BDX) announced the first prophylactic use of Phasix™ Mesh in Greece following its expanded CE-marked prophylactic indication in Europe, with the procedure performed at George Papanikolaou General Hospital in Thessaloniki.

The company reported the multicenter randomized PREVENT trial is >85% enrolled and is projected to complete enrollment in 2026, with results intended to support a U.S. PMA submission for incisional hernia prevention. Phasix launched three new sizes in 2025 and is registered in the U.K. Phasix is not indicated for hernia prevention in the United States.

Positive

• CE mark granted for broad prophylactic hernia indication in Europe
• PREVENT trial >85% enrolled and projected to finish enrollment in 2026
• Launched three new Phasix sizes in 2025
• Phasix registered in the U.K. and available across Europe

Negative

• Phasix is not indicated for hernia prevention in the United States
• Clinical evidence for U.S. prevention indication pending PREVENT trial completion

News Market Reaction

+2.06%

1 alert

+2.06% News Effect

On the day this news was published, BDX gained 2.06%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

PREVENT enrollment: over 85% Incisional hernia rate: up to 30% Fiscal 2025 revenue: $21.8 billion +5 more

8 metrics

PREVENT enrollment over 85% Target population treated in PREVENT randomized controlled trial

Incisional hernia rate up to 30% Patients affected after abdominal surgery

Fiscal 2025 revenue $21.8 billion Record revenue highlighted in DEF 14A

GAAP EPS $5.82 Fiscal 2025 GAAP EPS from proxy materials

Adjusted diluted EPS $14.40 Record fiscal 2025 adjusted diluted EPS

Capital returns $2.2 billion Returned via buybacks and dividends in fiscal 2025

Equity plan increase 3,935,000 shares Additional shares under 2004 equity-based compensation plan

Reverse Morris Trust cash $4 billion Expected cash to BD from Waters transaction

Market Reality Check

Price: $207.11 Vol: Volume 1,335,710 is below...

low vol

$207.11 Last Close

Volume Volume 1,335,710 is below 20-day average of 1,950,989 (relative volume 0.68) low

Technical Price 194.94 is trading above 200-day MA at 188.47

Peers on Argus

Peers show mixed moves: ALC -1.65%, RMD +1.27%, WST +0.42%, BAX +1.04%, HOLX +0....

Peers show mixed moves: ALC -1.65%, RMD +1.27%, WST +0.42%, BAX +1.04%, HOLX +0.01%, suggesting today’s setup is more stock-specific than broad sector-driven.

Historical Context

5 past events · Latest: Dec 18 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 18	Research collaboration	Positive	-0.3%	Teamed with Penn to develop high-parameter flow panel for 1,000-patient study.
Dec 15	Product expansion	Positive	-1.9%	IVDR certification for new VIASURE assays expanding BD MAX testing menu in Europe.
Dec 04	Strategic partnership	Positive	+0.1%	Partnered with ChemoGLO to pair BD HD Check with LC-MS/MS contamination testing.
Dec 03	Product launch	Positive	+1.6%	Launched new BD FACSDiscover A8 configurations to broaden access to spectral analysis.
Nov 24	Regional launch	Positive	-0.9%	Introduced Surgiphor wound irrigation system in select European countries after CE approval.

Pattern Detected

Recent product and collaboration announcements have produced modest, mixed single-day reactions, with several positive-sentiment releases followed by slight declines.

Recent Company History

Over the past few months, BD has focused on collaborations and portfolio expansion. In Nov–Dec 2025, it launched the Surgiphor irrigation system in Europe, introduced new BD FACSDiscover A8 configurations, partnered with ChemoGLO on hazardous‑drug testing, and expanded BD MAX assays via Certest. A Penn collaboration targets a 1,000-patient immune profiling study. Today’s Phasix™ Mesh hernia‑prevention milestone and PREVENT trial enrollment fit this broader strategy of strengthening surgical and life‑sciences offerings.

Market Pulse Summary

This announcement adds a notable step in BD’s surgical strategy, with the first European prophylacti...

Analysis

This announcement adds a notable step in BD’s surgical strategy, with the first European prophylactic Phasix™ Mesh laparotomy case and PREVENT trial enrollment above 85%. It complements recent launches and collaborations across diagnostics and surgery. Investors may track forthcoming PREVENT data, progress toward a U.S. PMA submission for hernia prevention, and how these advances integrate with BD’s broader portfolio and capital-allocation plans.

Key Terms

laparotomy, incisional hernias, randomized controlled trial, bioabsorbable, +3 more

7 terms

laparotomy medical

"first Phasix™ Mesh laparotomy reinforcement case performed in Greece"

A laparotomy is an operation in which a surgeon makes a sizable incision through the abdominal wall to access the internal organs for diagnosis, repair, or biopsy — like opening a car’s hood to inspect and fix the engine. For investors, laparotomy matters because it influences hospital resource use, treatment costs, device and supply demand, recovery times, and regulatory or clinical outcomes tied to medical products and services.

incisional hernias medical

"prophylactic bioabsorbable mesh placement to reduce the incidence of incisional hernias"

An incisional hernia is a weakness or gap in the abdominal wall that develops at the site of a previous surgical incision, allowing tissue or organs to push through and form a visible bulge, like an inner lining poking out through a worn spot in clothing. For investors, these hernias matter because they drive demand for surgical repairs, implants and follow-up care, influence healthcare costs and insurance payments, and can affect clinical trial results and regulatory approvals for related medical products.

randomized controlled trial medical

"PREVENT multicenter randomized controlled trial, conducted across sites"

A randomized controlled trial is a research method that tests the effects of a new idea or treatment by randomly dividing participants into two groups: one that receives the treatment and one that does not. This approach helps ensure that the results are fair and unbiased, providing clear evidence about whether the treatment actually works. Investors value such trials because they offer reliable information that can influence decision-making and reduce uncertainty.

bioabsorbable medical

"supporting prophylactic bioabsorbable mesh placement to reduce the incidence"

A bioabsorbable material is engineered to gradually dissolve and be absorbed or cleared by the body after it has fulfilled its medical role—like a temporary scaffold that disappears once tissue heals. Investors care because bioabsorbable products can cut the need for follow-up surgeries and long-term complications, affect regulatory approval and reimbursement prospects, and provide a competitive edge that can influence future sales and company valuation.

sigmoidectomy medical

"The patient, a 63-year-old male with multiple risk factors, underwent a sigmoidectomy"

A sigmoidectomy is a surgical procedure that removes the sigmoid colon, the S-shaped last section of the large intestine, typically to treat disease, blockages, or damaged tissue. For investors, the procedure matters because its frequency, typical recovery complexity, and required devices or hospital resources influence revenue for hospitals, makers of surgical tools and supplies, and costs for insurers—similar to how replacing a damaged section of plumbing requires specific parts and labor.

ce marking regulatory

"Phasix™ Mesh received CE marking approval for the prophylactic indication"

CE marking is a symbol placed on certain products showing they meet European Union safety, health and environmental rules required to sell them in the EU/EEA. For investors, it signals that a product has cleared a common regulatory hurdle—like a passport for market access—reducing legal and market-entry risk and often widening sales opportunities across European markets.

pma submission regulatory

"while also supporting PMA submission for an incisional hernia prevention indication"

A PMA submission is a formal application to the U.S. Food and Drug Administration seeking premarket approval for a high‑risk medical device by providing detailed safety and effectiveness evidence. For investors, PMA approval is a gatekeeper to commercial sales in the U.S.; receiving it can unlock significant revenue while delays, additional data requests, or rejection can push back market entry and increase development costs — think of it like applying for a very strict license to sell a new kind of vehicle.

AI-generated analysis. Not financial advice.

FRANKLIN LAKES, N.J., Jan. 5, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced a significant milestone in its advanced tissue regeneration strategy: the first Phasix™ Mesh laparotomy reinforcement case performed in Greece following the product's expanded indication for prophylactic use in Europe. This marks the first broad prophylactic indication of hernia mesh across open, high-risk procedures in the European Union.

The procedure was completed at George Papanikolaou General Hospital of Thessaloniki, one of the largest institutions in northern Greece, led by general surgeon and Associate Professor, Ioannidis Orestis. The patient, a 63-year-old male with multiple risk factors, underwent a sigmoidectomy, and a Phasix™ Mesh (08 x 30 cm) was placed prophylactically at the laparotomy incision site to reduce the likelihood of future hernia development.

Concurrently, BD's PREVENT multicenter randomized controlled trial, conducted across sites in both Europe and the United States, has treated over 85% of its target population and is projected to complete enrollment in 2026. The study aims to provide robust clinical evidence supporting prophylactic bioabsorbable mesh placement to reduce the incidence of incisional hernias, while also supporting PMA submission for an incisional hernia prevention indication in the United States.

"Incisional hernias affect up to 30% of patients after abdominal surgery and cost health care systems billions annually," said Rian Seger, worldwide president of the BD Surgery business. "With Phasix™ Mesh, we're not just repairing hernias—we're preventing them. This milestone reflects our commitment to improving long-term patient outcomes."

According to recent U.K. data, patients who undergo incisional hernia repair incur an average cost of £23,148—nearly double that of patients who do not require repair. Prevention strategies have the potential to significantly reduce these costs and improve patient quality of life.

Phasix™ Mesh received CE marking approval for the prophylactic indication and launched three new sizes in 2025. The product is now registered in the U.K. and available across Europe for broad hernia prophylaxis indications, marking a pivotal step toward redefining surgical best practices, helping clinicians deliver safer outcomes and improve efficiency in every procedure. Phasix™ Mesh is not indicated for use for hernia prevention in the United States.

About BD

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson

Contacts:
Media	Investors
Fallon McLoughlin Director, Public Relations 201.258.0361  Fallon.Mcloughlin@bd.com	Adam Reiffe Vice President, Investor Relations 201.847.6927         Adam.Reiffe@bd.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/bd-marks-milestone-with-first-phasix-hernia-prevention-case-in-greece-and-over-85-enrollment-in-us-prevent-trial-302652279.html

SOURCE BD (Becton, Dickinson and Company)

FAQ

What milestone did BD (BDX) announce on January 5, 2026 regarding Phasix Mesh in Greece?

BD reported the first prophylactic Phasix Mesh laparotomy reinforcement case in Greece at George Papanikolaou General Hospital.

How far along is the PREVENT trial for Phasix Mesh (BDX) and when will enrollment finish?

The PREVENT randomized trial is over 85% enrolled and is projected to complete enrollment in 2026.

Does Phasix Mesh have regulatory approval for hernia prevention in Europe and the U.S. (BDX)?

Phasix has a CE-marked prophylactic indication and is available across Europe, but it is not indicated for hernia prevention in the United States.

What product updates did BD (BDX) announce for Phasix Mesh in 2025?

BD launched three new Phasix Mesh sizes in 2025 to support broad prophylactic use in Europe.

How might Phasix Mesh prophylactic use affect healthcare costs cited in the announcement?

The release cites U.K. data showing incisional hernia repair costs averaging £23,148, suggesting prevention could reduce such costs.

Will PREVENT trial data be used to seek U.S. approval (BDX)?

Yes, the company says PREVENT aims to generate evidence to support a PMA submission for an incisional hernia prevention indication in the United States.